<DOC>
	<DOCNO>NCT01348100</DOCNO>
	<brief_summary>This study design 3-part trial evaluate safety novel depot formulation iloperidone , compare 2 depot dosage form , perform dose range 1 chosen form support monthly depot dose regimen . In Phase A , study design evaluate safety crystalline iloperidone depot formulation . In Phase B , pharmacokinetic safety profile 2 depot clinical dosage form compare , 1 form select assessment Phase C. Phase C study design define dose-exposure relationship select form provide information permit comparison risk-benefit ratio several dos study drug enable optimal dose selection later study .</brief_summary>
	<brief_title>Safety , Tolerability , Pharmacokinetics Iloperidone Depot Schizophrenic Patients</brief_title>
	<detailed_description />
	<mesh_term>Schizophrenia</mesh_term>
	<criteria>Patients schizophrenia stable 3 month . Women become currently pregnant lactating . Hypersensitivity iloperidone relate drug . Other protocoldefined inclusion/exclusion criterion may apply .</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>65 Years</maximum_age>
	<verification_date>December 2013</verification_date>
	<keyword>Schizophrenia</keyword>
	<keyword>Iloperidone</keyword>
	<keyword>Depot</keyword>
	<keyword>Injection</keyword>
</DOC>